Reaxa launches new peptide coupling agent

Related tags Peptide synthesis Reaxa

Avecia spin-out Reaxa has launched a new peptide coupling
technology based on 2-mercaptobenzothiazole (2-MBT), which it
claims offers major operational and cost benefits in both small and
large scale solid-phase peptide synthesis.

2-MBT active ester coupling technique avoids the safety issues associated with the widely used HOBt (1-Hydroxybenzotriazole) technology and offers a number of additional and significant advantages to the peptide industry, according to the firm. Benefits of the 2-MBT coupling agent over HOBt include a very significant reduction in raw material costs; improved solubility in typical processing solvents and no storage or transportation restrictions.

Reaxa's R&D team has shown the application and equivalence of 2-MBT thioesters for in-situ​ coupling procedures as a direct replacement for HOBt, with no change required to standard activation and coupling procedures.

"2-MBT fits Reaxa's agenda of safer, cleaner and more sustainable chemistry,"​ commented the company's chief technology officer, Dr David Pears.

"We see the clear cost reduction benefits being particularly attractive for large volume peptide production, with the technology accessed on a sub-licensed basis,"​ he added.

In addition to sub-licensing 2-MBT technology to peptide manufacturers, Reaxa offers a range of specialist services to support peptide drug discovery and process development - based largely on stakeholder Avecia's expertise in Fmoc solid-phase peptide synthesis.

Reaxa's lead business area is catalysis chemistry, based on a twin-track strategy to simplify processes, reduce metal contamination in products and process waste and aid catalyst recovery and re-cycling. The firm has a range of encapsulated catalysts (EnCat) as well as scavenging resins (QuadraPure) to improve clean-up in conventional, homogeneous chiral and non-chiral catalysis.

New EnCat catalysts and QuadraPure resins are in development for 2005/06 launch. Reaxa's new catalyst R&D programmes include nano particulate metal zero hydrogenation catalysts, chiral catalysts and biocatalyst immobilisation.

2-MBT was developed by Reaxa scientists and is one of a basket of technologies transferred or sub-licensed to Reaxa by Avecia - from which the new company was successfully spun-out in June this year.

Related news

Show more

Related product

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.